CHDR has devoted much of its own research to drug development methodology. Through systematic reviews, dedicated studies, academic networks, and its own expertise and collected database of 30 years of drug studies, CHDR has validated and optimized a unique set of methods and biomarkers, aimed to address every major question in early drug development.

At a glance

At 10% of our annual revenue a dedicated research budget is large enough to accommodate an ambitious research programme, which will facilitate CHDR's methodology development programme as well as Ready-4-Research and Trial@home.

In-house Medical Research Council

CHDR is an independent foundation without shareholders, and we have always used part of our revenue to finance research projects, in addition to conducting sponsored studies,’ says Prof Adam Cohen, CHDR’s CEO. ‘But now that our organisation ‒ and our annual revenue ‒ has grown, it has become important to structure this self-financed research. Most importantly, having a dedicated research budget gives us the freedom to decide which projects we want to fund.

Keeping track of immunosuppression

We recently launched a new project to develop, apply, and validate a battery of functional tests designed to measure immunosuppression in kidney transplant patients. This test battery will measure general immune status, patient-specific and antigen-specific responses, and the relationship between these responses and the drug’s concentration in the plasma. This project will result in a panel of diagnostic tests to help guide the pharmacological treatment of individual kidney transplant recipients, thereby minimising kidney damage, graft rejection, and the risk of immunodeficiency and/or drug toxicity. This multi-disciplinary project will capitalise on close collaboration between several research groups. CHDR will coordinate the project and will be responsible for the clinical pharmacology, and the Leiden University Medical Centre (LUMC) Pharmacy and the departments of Immunology, Nephrology, and Clinical Chemistry will be indispensable. Moreover, the Leiden Academic Centre for Drug Research (LACDR) will develop pharmacometrics models to correlate drug concentration with drug effects, and EMC will provide expert advice regarding transplantation immunology.

Responsible staff: Dr Matthijs Moerland and Prof Koos Burggraaf.

Request more information

Mitochondrial function and hip fractures

Another new study at CHDR is designed to measure mitochondrial dysfunction as a prognostic factor for predicting patient recovery following surgical hip fracture repair in elderly patients. This project will provide a detailed picture of the recovery process by measuring physical parameters on a daily basis using CHDR's Trial@Home. The measurements include the patient’s weight, body-mass index, physical activity, and metabolism. This project will be performed in collaboration with the LUMC’s Department of Orthopaedic Surgery, and local hospitals (e.g. Bronovo Hospital and Alrijne Hospital) will help recruit patients for the study.

Responsible staff: Dr Geert Jan Groeneveld.

Request more information